Recognising the importance of coordinated action and mutual responsibility for the health of Ukrainians, Arterium continues to help doctors in line with previous commitments. 

As part of the activities of a charity fund created to combat the spread of the COVID-19 infection, Arterium has provided a low-temperature medical freezer to the Kyiv Laboratory Centre of the Ministry of Health of Ukraine. More than 500 samples for coronavirus tests from Kyiv and the Kyiv Region are submitted to the laboratory daily. The freezer allows for the storage of samples at temperatures down to -86C, which increases the storage capacity of the analysed samples of nucleic acids, tissues, cells and also allows for the storage of biomaterials, reagents and test systems for PCR diagnostics.

The Arterium Corporation has introduced a product to prevent corneal edema: Terso drops. This product is designed and manufactured by the Italian pharmaceutical company DMG Italia srl. The company specialises in the production of innovative medicines, medical devices and dietary supplements. According to WHO statistics, one in ten patients with ophthalmic problems suffers from corneal edema.

The Arterium Corporation has introduced a new product – Umastar eye drops which are used for “dry eye” disease as a replacement for tears. According to ophthalmologists, almost every fifth adult on the planet suffers from this disease with a tendency to increase its prevalence. Umastar is designed and manufactured by the pharmaceutical company DMG Italia srl.

Corneal damage can happen for many reasons: injury, chemical or thermal burns, inflammation. However, the most common reason is getting a foreign body in the eye. Now the treatment of corneal damage has become more effective. Ukrainian pharmacies are now offering Ophthasiale eye drops. The drops are designed and manufactured by the Italian pharmaceutical company DMG Italia srl.

This January in Ukraine Arterium Corporation launched the generic medicine Rosuvastatin*, which is used in the comprehensive treatment of cardiovascular diseases (CVD).

Rosuvastatin belongs to a group of statins which are cholesterol-lowering drugs. Cholesterol is associated with the development of myocardial infarctions and strokes. By controlling cholesterol levels, Rosuvastatin can reduce the occurrence of such conditions and so increase life expectancy. Rosuvastatin is included in international guidelines for the treatment of coronary heart disease, of which the most common is CVD. The number of patients in Ukraine who regularly take statins is very low. Price factor plays an important role in this. The introduction of the new quality generic medicine Rosuvastatin from Arterium Corporation is our contribution to the health of Ukrainians.

* The generic medicine Rosuvastatin is manufactured by Biopharm Ltd., Poland, under a commercial agreement. Arterium Corporation's own Rosuvastatin is now in the final stages of development.